Stevanato Group has strengthened its collaboration with Microsoft Italy to meet the challenges the pharmaceutical glass industry is experiencing from the COVID-19 pandemic.
The group is playing a key role in the production of plastic components for diagnostic tests and glass primary packaging for drugs.
It provides packaging and syringes for the major international anti-COVID-19 vaccine programmes, as well as pharmaceutical inspection equipment.
Stevanato’s digital transformation plan includes the development of a series of applications that use Microsoft Mixed Reality technologies and which are designed to respond to the current needs of the pharmaceutical sector.
For example, a Virtual Audit plan was launched, thanks to which the Stevanato Group quality teams wear the Microsoft HoloLens2 holographic headset with integrated Dynamics Remote Assist.
This allows them to move throughout the installation to show customers in remote connection all processes, including production phases and lab testing.
This also makes it possible to perform a remote quality system audit to ascertain that the installation complies with required standards and customer needs without requiring an interruption in the pharmaceutical supply chain, which is even more strategic during the pandemic.
In addition, the HoloLens headset also makes it possible to perform the Virtual FAT (Factory Acceptance Test) — the final pre-delivery inspection that assures the remotely connected customer that the equipment is functioning properly.
While wearing the headset, a technician can demonstrate machine components, start it up and share documentation.
Remote acceptance of equipment for the inspection of drugs and vaccines being developed makes it possible to accelerate delivery to pharmaceutical companies, a critical factor in this period when the company has to manage large volumes on a short time frame.
The digital transformation process within Stevanato also includes the development of Artificial Intelligence to improve the performance of inspection systems and detection of defective glass containers filled with drugs.
The group recently launched a project designed to make inspection equipment supplied by the group even more intelligent.
Artificial Intelligence will help guarantee maximum quality to the pharmaceutical industry, by reducing potential errors and detecting defective products along the production line.
The integrity of the containers is essential and, thanks to Microsoft AI integrated into Stevanato’s inspection equipment, pharmaceutical companies will be able to make use of reliable algorithms to identify any defects.
False positives can be reduced by 10-fold, also decreasing container production waste, while the detection rate can be improved by 5%.
These projects are part of Stevanato’s broader Digital Transformation plan, which aims to complete its New Digital Ecosystem by 2022.
12.01.2021, Stevanato Group
News material on the Site is copyright and belongs to the Company or to its third party news provider, and all rights are reserved. Any User who accesses such material may do so only for its own personal use, and the use of such material is at the sole risk of the User. Redistribution or other commercial exploitation of such news material is expressly prohibited. Where such news material is provided by a third party, each User agrees to observe and be bound by the specific terms of use applying to such news material. We do not represent or endorse the accuracy or reliability of any of the info contained in any news or external websites referred to in the news.
Should the content or the design of these sites violate third parties rights or legal prescriptions, we kindly ask you to send us a respective message without invoice or cost. We guarantee that passages where the claim is considered as justified will be removed immediately, without any necessity to involve any lawyer into this issue. We will reject any claim caused by submission of a honorary note in this regard without any prior contact and confirmation of the issueby us and we reserve the right ssue counter claim ourselves because of violation of aforesaid conditions.